8-K current report · filed Nov 17, 2026

Inhibrx Biosciences, Inc. (INBX) 8-K Current Report: November 17, 2026

Item 8.01Item EX-99.1INBX overview

Short answer

Inhibrx Biosciences, Inc. (INBX) filed an 8-K current report with the SEC on November 17, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Updated clinical data for ozekibart, or INBRX-109, in relapsed or refractory Ewing sarcoma.

Inhibrx Biosciences, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Updated clinical data for ozekibart, or INBRX-109, in relapsed or refractory Ewing sarcoma
  • Phase 1/2 expansion study evaluates ozekibart combined with irinotecan and temozolomide
  • Data presentation at the Connective Tissue Oncology Society 2026 Annual Meeting
  • Investor focus: efficacy and safety results could influence ozekibart’s development prospects and valuation

Item EX-99.1 · Exhibit EX-99.1

  • Updated Phase 1/2 Ewing sarcoma data: 62.7% ORR and 86.3% DCR among 51 response-evaluable patients
  • Responses included 2 complete responses and 30 partial responses, with 18 patients achieving benefit exceeding 6 months
  • Median PFS 6.0 months, exceeding historical irinotecan-temozolomide benchmarks of roughly 3 to 4 months
  • 22 of 60 treated patients remained on active treatment, supporting continued clinical momentum
  • FDA accepted ozekibart’s chondrosarcoma BLA for filing, creating a separate regulatory catalyst beyond Ewing sarcoma

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Inhibrx Biosciences, Inc. 8-K filings

Get the next INBX 8-K as it lands

Follow INBX for push alerts, or ask the research agent what this filing means.